Gillian Woollett Gives Insight Into What the US Can Learn From Europe's Biosimilar Adoption

Gillian Woollett, MA, Dphil, vice president and head of regulatory strategy and policy at Samsung Bioepis, explains why there's no easy to solution to getting the US biosimilar market to the same level as Europe.

Transcript

What can the United States learn from other countries regarding how to increase uptake and acceptance of biosimilars?

Woollett: I think the uptake acceptance thing is different because then you're getting into the nature of our health care system having so many different payers. But to the extent that the uptake is held up by physicians not being sure of biosimilars, then the real-world evidence and experience from Europe will be super useful. The issues around financial incentives, those are tough ones. Those are integral to the US system. And I think that's going to have to be dealt with elsewhere and obviously, things like rebates were part of the discussion, but I'm not sure anybody had a simple solution.